Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Apoptosis resistance contributes to treatment failure in colorectal cancer (CRC). New treatments that reinstate apoptosis competency have potential to improve patient outcome but require predictive biomarkers to target them to responsive patient populations. Inhibitor of apoptosis proteins (IAPs) suppress apoptosis, contributing to drug resistance; IAP antagonists such as TL32711 have therefore been developed. We developed a systems biology approach for predicting response of CRC cells to chemotherapy and TL32711 combinations in vitro and in vivo. CRC cells responded poorly to TL32711 monotherapy in vitro; however, co-treatment with 5-fluorouracil (5-FU) and oxaliplatin enhanced TL32711-induced apoptosis. Notably, cells from genetically identical populations responded highly heterogeneously, with caspases being activated both upstream and downstream of mitochondrial outer membrane permeabilisation (MOMP). These data, combined with quantities of key apoptosis regulators were sufficient to replicate in vitro cell death profiles by mathematical modelling. In vivo, apoptosis protein expression was significantly altered, and mathematical modelling for these conditions predicted higher apoptosis resistance that could nevertheless be overcome by combination of chemotherapy and TL32711. Subsequent experimental observations agreed with these predictions, and the observed effects on tumour growth inhibition correlated robustly with apoptosis competency. We therefore obtained insights into intracellular signal transduction kinetics and their population-based heterogeneities for chemotherapy/TL32711 combinations and provide proof-of-concept that mathematical modelling of apoptosis competency can simulate and predict responsiveness in vivo. Being able to predict response to IAP antagonist-based treatments on the background of cell-to-cell heterogeneities in the future might assist in improving treatment stratification approaches for these emerging apoptosis-targeting agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the IAP antagonist TL32711 was demonstrated to sensitize CRC cell lines to 5-FU- or oxaliplatin-induced cell death [144].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Since pre-existing or acquired resistance to apoptosis significantly contributes to treatment failure in colon cancer and other malignant neoplasms (4), the evaluation of new treatment combinations which re-instate apoptosis competency has the potential to improve patient outcome and survival.”
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“Adjuvant 5-FU/oxaliplatin treatment in stage III benefits only 15%-20% of patients, and many of these patients subsequently relapse (1).”
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218 · cited 1×
“…initial rapid degradation induced by IAP antagonists; this is because cIAP1 acts as an E3 ligase for cIAP2 and degradation of cIAP1/2 leads to activation of the non-canonical NF κ B pathway resulting in increased expression of NF κ B-driven genes, including BIRC3, the gene encoding cIAP2 (13,14).”
IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis
Vince, J. E., Wong, W. W.-L., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.037 · Cited by 1,053 · cited 1×
“…initial rapid degradation induced by IAP antagonists; this is because cIAP1 acts as an E3 ligase for cIAP2 and degradation of cIAP1/2 leads to activation of the non-canonical NF κ B pathway resulting in increased expression of NF κ B-driven genes, including BIRC3, the gene encoding cIAP2 (13,14).”
Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D. P., Langlais, C., Hupe, M., Cain, K., MacFarlane, M., Häcker, G., & Leverkus, M. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.011 · Cited by 860 · cited 1×
“IAP antagonist-dependent degradation of cIAPs can induce intrinsic ripoptosome formation (30,31), a finding we could confirm in CRC cells treated with TL32711.”
Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., Zachariou, A., Lopez, J., MacFarlane, M., Cain, K., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.006 · Cited by 820 · cited 2×
“Interestingly, in contrast to work in fibrosarcoma, breast adenocarcinoma, rhabdomyosarcoma or ovarian carcinoma cell lines (16), chemotherapy alone was not sufficient to induce ripoptosome formation in CRC cells, but significantly enhanced the limited ripoptosome formation observed after TL32711…”
IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer
Gyrd-Hansen, M., & Meier, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2889 · Cited by 790 · cited 1×
“IAP antagonists also bind to and trigger the rapid degradation of cellular IAP (cIAP) 1 and 2 [9], both of which are critical regulators of ripoptosome formation and caspase-8-dependent apoptosis induction in response to intrinsic pro-apoptotic stress and activation of tumour necrosis factor receptor (TNFR) family [6,…”
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752 · cited 1×
“The Bcl-2 antagonist venetoclax/ABT-199 has recently been approved for the treatment of patients with 17p deleted chronic lymphocytic leukemia and is currently being tested in additional cancer entities (5).”
The mathematics of cancer: integrating quantitative models
Altrock, P. M., Liu, L. L., & Michor, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4029 · Cited by 685 · cited 1×
“Moreover, this basic framework could be extended to take account of the influence of tumour architectures, vascularisation, microenvironmental heterogeneities as well as whole body drug PK/PD (36,37).”
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A. P., et al. (2000) · PubMed · Cited by 620
Research works printed but not linked: 1
- Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011;43:432–48. · DOI · Paper page
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Furthermore, the IAP antagonist TL32711 was demonstrated to sensitize CRC cell lines to 5-FU-or oxaliplatin-induced cell death [144].”
The Multiple Roles of the IAP Super-family in cancer
Kumar, S., Fairmichael, C., Longley, D. B., & Turkington, R. C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107610 · Cited by 76
Self-citationLi, J., Qin, X., Wu, R., Wan, L., Zhang, L., & Liu, R. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15162 · Cited by 58
RetractedGharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 64
An Updated Review of Smac Mimetics, LCL161, Birinapant, and GDC-0152 in Cancer Treatment
Chang, Y.-C., & Cheung, C. H. A. (2020) · Applied Sciences · doi:10.3390/app11010335 · Cited by 53
“In addition, birinapant degrades IAPs, activates the non-canonical NF-κB signaling pathway once the IAPs are degraded, and stabilizes mitogen-activated protein kinase 14 (MAP3K14) (NF-κB-inducing kinase), resulting in the activation of the non-canonical NF-κB signaling pathway [84,86].”
Background
Metadata
- Authors
- Crawford, N., Salvucci, M., Hellwig, C. T., Lincoln, F. A., Mooney, R. E., O’Connor, C. L., Prehn, J. H., Longley, D. B., & Rehm, M.
- Affiliations
- Queen's University Belfast (GB)
- Royal College of Surgeons in Ireland (IE)
- University of Stuttgart (DE)
- Corresponding author
- Longley, Daniel B
- Rehm, Markus
- Venue
- Cell Death & Differentiation
- Published
- 2018-03-02
- Volume
- 25
- Issue
- 11
- Pages
- 1952-1966
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- PMC
- PMC5989936
- OpenAlex
- W2792588470
- Cited by
- 22
- References
- 38
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 7 · 2019: 1 · 2018: 1
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by-nc-sa)
- Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
- Funders
- Department for Employment and Learning, Northern Ireland
- Wellcome Trust (110371)
- Health Research Board (RP/2006/258)
- Cancer Research UK (24387, A4220)
- European Commission
- Science Foundation Ireland (14/IA/2582, 09/RFP/BIC2375, 13/IA/1881)
- Public Health Agency (STL/5175/15)
- Deutsche Forschungsgemeinschaft (FOR‐2036, MO 3226/1‐1, 13/IA/1881)
- Irish Research Council (GOIPG/2014/1299, GOIPD/2013/102)
- Medical Research Council (MC_PC_17117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- colorectal cancer, IAP antagonists, birinapant, apoptosis resistance, combination chemotherapy, 5-fluorouracil, oxaliplatin, caspase activation, cellular heterogeneity, predictive biomarkers, tumor growth inhibition
- MeSH terms
- Oxaliplatin, Mitochondrial Permeability Transition Pore, Animals, Antineoplastic Agents, Colonic Neoplasms, Dipeptides, Drug Therapy, Combination, Female, Fluorouracil, Humans, Indoles, Mice, Inbred BALB C, Models, Theoretical, Apoptosis, Mitochondrial Membrane Transport Proteins, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, Inhibitor of Apoptosis Proteins, Mice, X-Linked Inhibitor of Apoptosis Protein, Receptor-Interacting Protein Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. https://app.cochat.ai/papers/10.1038/s41418-018-0082-y
- The paper
- Crawford, N., Salvucci, M., Hellwig, C. T., Lincoln, F. A., Mooney, R. E., O’Connor, C. L., Prehn, J. H., Longley, D. B., & Rehm, M. (2018). Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. Cell Death & Differentiation. https://doi.org/10.1038/s41418-018-0082-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.